KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Utilizing Antigenic Peptide and Adhesion Molecule Conjugates to Suppress Autoimmune Disease in Animal Models

    Thumbnail
    View/Open
    Buyuktimkin_ku_0099D_11810_DATA_1.pdf (12.22Mb)
    Issue Date
    2011-12-31
    Author
    Buyuktimkin, Barlas
    Publisher
    University of Kansas
    Format
    156 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author.
    Metadata
    Show full item record
    Abstract
    Peptides and proteins have been used as carriers to target and deliver molecules to sites of action. Conjugating a drug to a macromolecule offers the unique advantage of being able to target drug to a specific cell surface receptor with high affinity, thereby increasing efficacy and reducing side effects. Furthermore, conjugations between two different peptides, or between peptide and protein, that have activities to modulate two receptors have shown promising results in suppressing autoimmune diseases in animal models. Therefore, the objective of the dissertation was to explore the possibility of selectively targeting peptide and protein conjugates to antigen presenting cells to suppress autoimmune diseases. The I-domain of leukocyte function associated antigen-1 (LFA-1) conjugated to antigenic PLP139-151 peptide (IDAC-3) suppressed experimental autoimmune encephalomyelitis (EAE) when delivered in a vaccine-like manner by shifting the immune balance away from Th17-mediated pathology by increasing involvement of T-reg cells (Chapter 2). PLP139-151 conjugated to LABL adhesion peptide (Ac-PLP-BPI-NH2-2) was formulated in a colloidal gel for a one-time subcutaneous administration to suppress EAE. A vaccine-like administration of the peptide conjugate suppressed EAE as well as the relapse. In vitro cytokine studies suggested that the mechanism of suppression was due to the shift of the immune balance away from a Th17-mediated response (Chapter 3). The utility of BPI to target other autoimmune diseases such as collagen-induced arthritis (CIA) was also investigated. Here, collagen type II peptides were conjugated to LABL (CII-BPI). It was found that suppression of disease is dependent upon the sequence of the antigen, and that the mechanism of disease suppression was linked to a shift in the immune balance from a proinflammatory to a regulatory response (Chapter 4).
    URI
    http://hdl.handle.net/1808/9731
    Collections
    • Dissertations [3313]
    • Pharmaceutical Chemistry Dissertations and Theses [90]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps